Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease

OBJECTIVE: To estimate the cost-effectiveness of adalimumab plus methotrexate (MTX) versus MTX monotherapy in early, aggressive rheumatoid arthritis (RA) when explicitly modelling short-term (reversible) and long-term (irreversible, ie, joint damage) disease activity and physical function. METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Stephens, Stephanie, Botteman, Marc F, Cifaldi, Mary A, van Hout, Ben A
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2015
Assuntos:
Rheumatology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4466612/
https://ncbi.nlm.nih.gov/pubmed/26059521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2014-006560
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados